Jenkins, V. et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 94, 828-834

Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, East Sussex BN1 9QG, UK.
British Journal of Cancer (Impact Factor: 4.84). 04/2006; 94(6):828-34. DOI: 10.1038/sj.bjc.6603029
Source: PubMed


The neuropsychological performance of 85 women with early stage breast cancer scheduled for chemotherapy, 43 women scheduled for endocrine therapy and/or radiotherapy and 49 healthy control subjects was assessed at baseline (T1), postchemotherapy (or 6 months) (T2) and at 18 months (T3). Repeated measures analysis found no significant interactions or main effect of group after controlling for age and intelligence. Using a calculation to examine performance at an individual level, reliable decline on multiple tasks was seen in 20% of chemotherapy patients, 26% of nonchemotherapy patients and 18% of controls at T2 (18%, 14 and 11%, respectively, at T3). Patients who had experienced a treatment-induced menopause were more likely to show reliable decline on multiple measures at T2 (OR=2.6, 95% confidence interval (CI) 0.823-8.266 P=0.086). Psychological distress, quality of life measures and self-reported cognitive failures did not impact on objective tests of cognitive function, but were significantly associated with each other. The results show that a few women experienced objective measurable change in their concentration and memory following standard adjuvant therapy, but the majority were either unaffected or even improve over time.

Download full-text


Available from: Valerie Shilling,
    • "A recurrent finding regarding the relationship between objective and subjective measures of cognitive impairment is that these are not associated ( Hermelink et al , 2010 ; Pullens et al , 2010 ; Hutchinson et al , 2012 ) . Although there is emerging evidence to show that SCI in cancer patients may be related to both neuropsychological outcomes ( Ganz et al , 2013 , 2014 ) and to altered functional , morphological , and electrophysiological brain properties ( Deprez et al , 2011 , 2014 ; McDonald and Saykin , 2013 ; Hunter et al , 2014 ) , SCI appears to be more strongly associated with psychological distress , for example , symptoms of depression and anxiety ( Van Dam et al , 1998 ; Jenkins et al , 2006 ; Pullens et al , 2013 ) . However , even if SCI was not , altogether , related to objective impairment , it inarguably remains an equally important research area in psychosocial cancer research , due to the well - known association between SCI and survivors ' quality of life ( Boykoff et al , 2009 ; Calvio et al , 2010 ; Wu et al , 2011 ; Von et al , 2013 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is growing concern among breast cancer (BC) patients and survivors about cognitive impairment following systemic treatments. The aim of the present study was to investigate the long-term effects of standard systemic adjuvant therapies on subjective cognitive impairment (SCI) in a large nationwide cohort of BC survivors 7-9 years after primary surgery. Participants were recruited from the nationwide Psychosocial Factors and Breast Cancer inception cohort of Danish women treated for primary BC. SCI was assessed with the Cognitive Failures Questionnaire and women allocated to systemic treatment according to nationwide standard protocols were compared with women who had not received any systemic treatments. A total of 1889 recurrence-free survivors were eligible for analysis. No difference in SCI was found between survivors across standardized systemic treatment protocols when analyses were stratified by menopausal status and adjusted for possible sociodemographic and treatment-related confounders. The frequency of significant SCI in a subgroup of survivors in the age range 65-74 years was ∼7%. No differences in long-term SCI at 7-9 years post surgery were found between women who had received systemic therapies and those who had not. Furthermore, the observed proportion of survivors with significant SCI was comparable to normative data. These results are important to communicate to patients, survivors, and clinicians alike, especially in the light of increasing concern about cognitive impairment following systemic therapies.British Journal of Cancer advance online publication, 14 July 2015; doi:10.1038/bjc.2015.243
    British Journal of Cancer 07/2015; 113(5). DOI:10.1038/bjc.2015.243 · 4.84 Impact Factor
  • Source
    • "Aromatase inhibitors are suspected of inducing subtle hippocampusdependent memory deficits in women, as shown in our recent functional magnetic resonance imaging (fMRI) study (Bayer et al., 2015) and clinical pilot experiments (Collins et al., 2009; Hurria et al., 2014; Jenkins et al., 2006). Given this background, we decided to investigate putative associations between inhibition of hippocampal aromatase, hippocampal LTP, and hippocampus-dependent behavior. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In estrogen-induced synaptic plasticity, a correlation of structure, function and behavior in the hippocampus has been widely established. 17ß-estradiol has been shown to increase dendritic spine density on hippocampal neurons and is accompanied by enhanced long-term potentiation and improved performance of animals in hippocampus-dependent memory tests. After inhibition of aromatase, the final enzyme of estradiol synthesis, with letrozole we consistently found a strong and significant impairment of long-term potentiation (LTP) in female mice as early as after six hours of treatment. LTP impairment was followed by loss of hippocampal spine synapses in the hippocampal CA1 area. Interestingly, these effects were not found in male animals. In the Morris water maze test, chronic administration of letrozole did not alter spatial learning and memory in either female or in male mice. In humans, analogous effects of estradiol on hippocampal morphology and physiology were observed using neuroimaging techniques. However, similar to our findings in mice, an effect of estradiol on memory performance has not been consistently identified/observed. Copyright © 2015. Published by Elsevier Inc.
    Hormones and Behavior 05/2015; 74. DOI:10.1016/j.yhbeh.2015.05.008 · 4.63 Impact Factor
  • Source
    • "Five meta-analyses have also documented cognitive deficits that survivors experience , suggesting that impairments in memory, attention and concentration, speed of processing, and executive functioning are most common (Anderson-Hanley et al., 2003; Falleti et al., 2005; Jansen et al., 2005; Jim et al., 2012; Stewart et al., 2006). Although results of some prospective studies suggest cognitive impairment may attenuate over time (Jenkins et al., 2006; Tchen et al., 2003; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004), researchers have found that a substantial number of survivors continue to have objectively measured memory deficits for 5, 10, and even as long as 20 years post-treatment (Ahles et al., 2002; Jenkins et al., 2006; Koppelmans et al., 2012; Wefel et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive impairment is a distressing, disruptive, and potentially debilitating symptom that can occur as a direct result of cancer or its treatment. National organizations have identified cognitive impairment as a challenge many survivors face and call for research to address this problem. Despite the priority, research is still relatively limited and questions remain unanswered about prevalence and impact on survivors, as well as coping strategies and effective treatment options available to address this potentially debilitating problem. The purpose of this article is to (a) analyze the prevalence and types of cognitive impairment that commonly affect survivors; (b) delineate the impact that cognitive impairment after cancer and cancer treatment has on self-esteem, social relationships, work ability, and overall quality of life among survivors; and (c) synthesize and appraise commonly used coping strategies used by survivors to address cognitive impairment and evidence-based interventions that may be incorporated into clinical practice. A comprehensive review and synthesis of the literature was conducted. Evidence-based interventions to address cognitive changes after cancer and cancer treatment are limited. However, emerging research has demonstrated that nonpharmacologic treatments, such as cognitive training, are likely to be effective.
    Clinical journal of oncology nursing 02/2015; 19(1):47-56. DOI:10.1188/15.CJON.19-01AP · 0.91 Impact Factor
Show more